included 15,752 patients with diabetes mellitus type 2 from the Yinzhou district in China and observed a significantly increased risk of hospitalisation for heart failure in patients treated with sulfonylurea derivate monotherapy compared to acarbose monotherapy (an alpha-glucosidase inhibitor preventing intestinal glucose absorption with neutral effects on heart failure that is not commonly prescribed in the Netherlands) (HR 1.61 (95% CI 1.14–2.27)) [14]. Here, GAA is linked to heart failure.